Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Share-based Compensation (2016 - 2026)

Ocular Therapeutix has reported Share-based Compensation over the past 14 years, most recently at $15.6 million for Q1 2026.

  • For Q1 2026, Share-based Compensation rose 49.02% year-over-year to $15.6 million; the TTM value through Mar 2026 reached $48.3 million, up 35.75%, while the annual FY2025 figure was $43.2 million, 30.43% up from the prior year.
  • Share-based Compensation for Q1 2026 was $15.6 million at Ocular Therapeutix, up from $11.4 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $15.6 million in Q1 2026 and troughed at $4.2 million in Q1 2022.
  • A 5-year average of $7.5 million and a median of $6.6 million in 2024 define the central range for Share-based Compensation.
  • Biggest five-year swings in Share-based Compensation: surged 155.9% in 2024 and later dropped 14.3% in 2025.
  • Year by year, Share-based Compensation stood at $4.2 million in 2022, then grew by 2.22% to $4.3 million in 2023, then skyrocketed by 66.29% to $7.2 million in 2024, then skyrocketed by 57.83% to $11.4 million in 2025, then surged by 37.18% to $15.6 million in 2026.
  • Business Quant data shows Share-based Compensation for OCUL at $15.6 million in Q1 2026, $11.4 million in Q4 2025, and $11.7 million in Q3 2025.